Pentazocine And Naloxone

Pentazocine And Naloxone

Pentazocine And Naloxone Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Drug Dependence. Pentazocine can cause a physical and psychological dependence. (See DRUG ABUSE AND DEPENDENCE.)

Head Injury and Increased Intracranial Pressure. As in the case of other potent analgesics, the potential of pentazocine for elevating cerebrospinal fluid pressure may be attributed to CO2 retention due to the respiratory depressant effects of the drug. These effects may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, pentazocine can produce effects which may obscure the clinical course of patients with head injuries. In such patients, pentazocine must be used with extreme caution and only if its use is deemed essential.

Usage with Alcohol. Due to the potential for increased CNS depressant effects, alcohol should be used with caution in patients who are currently receiving pentazocine.

Patients Receiving Narcotics. Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic dependence, have experienced withdrawal symptoms after receiving pentazocine.

Certain Respiratory Conditions. Although respiratory depression has rarely been reported after oral administration of pentazocine, the drug should be administered with caution to patients with respiratory depression from any cause, severely limited respiratory reserve, severe bronchial asthma, and other obstructive respiratory conditions, or cyanosis.

Acute CNS Manifestations. Patients receiving therapeutic doses of pentazocine have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be very closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.)

Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain.

Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only.

History

There is currently no drug history available for this drug.

Other Information

Pentazocine and naloxone hydrochlorides tablets USP contain pentazocine hydrochloride USP, equivalent to 50 mg base, a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride USP, equivalent to 0.5 mg base.

Pentazocine and naloxone hydrochlorides tablets are an analgesic for oral administration.

Chemically, pentazocine hydrochloride is (2R*, 6R*, 11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol hydrochloride, a white, crystalline substance soluble in acidic aqueous solutions. It has the following structural formula:

Figure 1

C19H27NO•HCI        Molecular Weight 321.88

Chemically, naloxone hydrochloride is 17-AIlyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride. It is a slightly off-white powder, and is soluble in water and dilute acids. It has the following structural formula:

Figure 2

C19H21N04•HCI        Molecular Weight 363.84

Each tablet, for oral administration, contains pentazocine hydrochloride USP, equivalent to 50 mg of pentazocine, and naloxone hydrochloride USP, equivalent to 0.5 mg of naloxone. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, dibasic calcium phosphate, D&C Yellow No. 10 Al-lake, FD&C Blue No. 1 Al-lake, FD&C Yellow No. 6 Al-lake, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium lauryl sulfate.

Pentazocine And Naloxone Manufacturers


  • Keltman Pharmaceuticals Inc.
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Keltman Pharmaceuticals Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Pd-rx Pharmaceuticals, Inc.]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc]
  • Bryant Ranch Prepack
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Bryant Ranch Prepack]
  • Watson Laboratories, Inc.
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Watson Laboratories, Inc.]
  • Golden State Medical Supply, Inc.
    Pentazocine And Naloxone (Pentazocine Hydrochloride And Naloxone Hydrochloride) Tablet [Golden State Medical Supply, Inc.]

Login To Your Free Account